Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Efficacy and Safety of 3 Dose Levels of KVD824, an Oral Plasma Kallikrein Inhibitor, for Long-Term Prophylactic Treatment of Hereditary Angioedema Type I or II

Next Previous
Trial Profile

Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Efficacy and Safety of 3 Dose Levels of KVD824, an Oral Plasma Kallikrein Inhibitor, for Long-Term Prophylactic Treatment of Hereditary Angioedema Type I or II

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs KVD 824 (Primary)
  • Indications Hereditary angioedema
  • Focus Proof of concept; Therapeutic Use
  • Acronyms KOMPLETE
  • Sponsors KalVista Pharmaceuticals

Most Recent Events

  • 04 Oct 2022 According to Kalvista Pharmaceuticals media release, the company will proceed to finalize the database of the trial and assess the unblinded data for efficacy and safety to determine the potential for any further development.
  • 04 Oct 2022 Results published in the Kalvista Pharmaceuticals Media Release.
  • 04 Oct 2022 According to Kalvista Pharmaceuticals media release, the company has terminated the study. This decision was based on the observation of liver enzyme (ALT/AST) elevations in multiple patients in all treatment groups of the trial. This will have no impact on Sebetralstat expected safety profile or Phase 3 KONFIDENT trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top